← All trials
NCT03178032
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2017
- Primary completion
- Aug 30, 2019
- Completion date
- Dec 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Clinica Universidad de NavarraLead sponsor
- DNAtrix, Inc.Collaborator
- Alcyone Lifesciences, Inc.Collaborator
- Clinica Universidad de NavarraReponsible party - principal investigator
- Clinica Universidad de NavarraOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.